NewsRoom Articles - Page 102 of 154 - PsychedelicNewsWire (PNW)

MondayApr 12, 2021 3:00 pm

New UCSF Research Program to Focus on Psychedelics Research and Treatments’ Advancement

The formation of the University of California Neuroscape Psychedelics Division will help advance psychedelic research on brain health through $6.4 million in private financing. The new division at UCSF will employ a translational research approach that will integrate psychedelic treatment with groundbreaking neuroscience technology. The first project to be undertaken will be a MAPS phase 3 trial for the evaluation of MDMA, commonly known as ecstasy, as a new PTSD treatment. Neuroscape executive director Adam Gazzaley stated that the financiers of the center are helping facilitate a great leap forward in producing evidence of the clinical safety and effectiveness of…

MondayApr 12, 2021 2:10 pm

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Signs Letter of Intent to Co-Develop Psychedelic Mushroom-Based Psilocybin Formulations

PULL signs Letter of Intent with Psyence Group to co-develop extraction techniques for production of psilocybin drug formulations Psyence is one of world’s first psychedelic mushroom companies operating a federally legal commercial cultivation and extraction facility PULL operates best-in-class processing infrastructure under Standard Processing License by Health Canada Near term milestones include Canada-based human clinical trials Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, recently signed a Letter of Intent with the Psyence Group to develop premium extraction techniques for the production of…

MondayApr 12, 2021 1:01 pm

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Files First Order for Rapid COVID Test Kits Amid European Regulatory Approval

Bioscience technology accelerator XPhyto Therapeutics Corp. recently announced it had placed its first order for its Covid-ID Lab rapid, portable virus test from its German development partner XPhyto received approval for the test kit last month from European regulators with oversight of in vitro diagnostic device (CE-IVD) use certification and the internationally agreed-on ISO 13485 medical product quality standards The Covid-ID Lab is designed to help beleaguered industries and government regulators quickly screen for the COVID-19 virus at point-of-care sites, and the company expects to begin sales and distribution in April XPhyto has just completed a rebranding effort that includes…

FridayApr 09, 2021 2:44 pm

Integration Proves Its Importance When Treating Mental Conditions Using Psychedelics

For a big chunk of his adult life, Nick Watchorn suffered from serious PTSD, before seeking psychedelic treatments, which helped him manage his condition. Watchorn revealed that the psychoactive sessions he attended and the work that he did on himself afterwards, through a process he refers to as integration, saved his life. He states that before he received the therapeutic treatments (MDMA-assisted therapy), he thought he was too far gone. Watchorn, now 54, had been plagued for more than two decades by the memories of a mass shooting that he’d experienced as a young police officer. The shooting, which occurred…

ThursdayApr 08, 2021 2:25 pm

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Commercialization Team Set to Launch Rapid POC COVID Test Solution

Bioscience technology accelerator XPhyto Therapeutics Corp. is working with development partner 3a-diagnostics GmbH to roll out its pandemic-related virus diagnostic tool for the European market planned in April The test solution, dubbed “Covid-ID Lab,” received European regulatory approval last month XPhyto’s product is designed to be portable and rapid in its response time to help decrease testing operation costs and increase convenience of use News reports about the COVID-19 pandemic reflect a growing optimism that vaccine, mask and distancing protocols may be helping to drive down infection rates, although the reports note the virus continues to have a deadly effect…

ThursdayApr 08, 2021 11:15 am

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) at Front of Line for Cutting-Edge Vitalis Extraction Technology

Annual growth of 17% is forecast for cannabis extraction market to reach $28.5 billion by 2027 Pure Extracts Technologies is already operating leading extraction systems from Vitalis and will soon become one of the first companies to have Vitalis’ new Cosolvent Injection System (“CIS”) The CIS delivers dramatically faster throughput capacities, even higher-quality cannabis extracts, optimal ethanol cosolvent flow rates and low ethanol usage Analysts are aligned on the future of the cannabis extraction market, with expectations for years of double-digit compound annual growth rates. The market experts at Grand View Research see 16.6% CAGR for the market to reach…

ThursdayApr 08, 2021 10:00 am

Three Studies Investigate the Role of Psychedelics in Treating OCD

Recent psychedelic research has led to significant breakthroughs in the field. The substances have been found to be useful in treating various mental health conditions such as depression as well as addiction. Additionally, new research has found that psilocybin, which is the active ingredient in magic mushrooms, is useful in treating obsessive-compulsive disorder (“OCD”). There are three studies looking into the use of psilocybin to decrease the symptoms of obsessive-compulsive disorder. While each study is using different treatment techniques, the evidence they’ve uncovered may be crucial in helping researchers understand the therapeutic mechanism behind psychedelic drugs. Generally, OCD is characterized…

WednesdayApr 07, 2021 12:30 pm

Psilocybin Has Potential to Curb the Global Obesity Crisis

Psychedelics substances such as psilocybin have been found to be helpful in treating obesity and weight issues. Healthline found that more than one-third of adults in America are obese. Nearly 17% of children, ages 2 to 19, are also considered obese. Additionally, obesity has been linked to more than 60 chronic illnesses, including cancer, stroke, heart disease and type 2 diabetes. Worldwide, obesity has gotten worse, and if a substance such as psilocybin can help fight obesity and weight issues, we may be looking at a potential game changer. Various psychedelic companies have been studying psychedelics, looking for ways to…

TuesdayApr 06, 2021 1:23 pm

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Completes Pre-Clinical Studies, Progresses Two Drug Candidates

Cybin has completed more than 20 pre-clinical studies in record time. Company is advancing two new therapeutic candidates with enhanced, improved properties. Drug candidates are designed to treat serious psychiatric conditions with high unmet medical needs. Cybin (NEO: CYBN) (OTCQB: CLXPF), a leading biotech company focused on progressing psychedelic therapeutics, has completed key research studies both in vitro and in vivo. The company recently announced that it had completed its 20th pre-clinical study and had progressed two psychedelic investigational new drug candidates: CYB003 and CYB004 (https://ibn.fm/jDvFz). The studies were completed in record time, the company reported, in part because of close collaboration with…

TuesdayApr 06, 2021 12:30 pm

Researchers Find Traits That May Help Identify Study Subjects Who Could Benefit from Psychedelic Therapy

The number of studies that focus on psychedelics and the benefits they possess as therapies for various mental health conditions has increased tremendously in the last few years. Psychedelics such as LSD and psilocybin mushrooms have shown their potential as possible therapies for conditions such as depression and PTSD, and while many hope that these drugs will be approved as therapies soon, there are those who are concerned about the effects these drugs may have on patients who participate in clinical trials for their study. New research has identified traits that have been linked to negative and positive experiences on…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000